TIM-3 inhibitors: a promising strategy for tumor immunotherapy

被引：1

作者：

Lu, Lu ^{[1
]}

Deng, Liufu ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Shanghai Frontiers Sci Ctr DrugTarget Identificat, Sch Pharmaceut Sci, Natl Key Lab Innovat Immunotherapy, Shanghai 200240, Peoples R China

来源：

TRENDS IN MOLECULAR MEDICINE | 2024年 / 30卷 / 03期

基金：

中国国家自然科学基金;

关键词：

D O I：

10.1016/j.molmed.2024.01.004

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Ma et al. recently reported a systematic screening of small -molecule compounds targeting the FG-CC' cleft of T cell immunoglobulin and mucin-containing molecule 3 (TIM3). They identified a functional Tim3 inhibitor, ML -T7, that, as a single agent or in combination with antiPD -1, demonstrated strong antitumor activity in preclinical mouse tumor models, supporting its poten

引用

页码：202 / 203

页数：2

共 50 条

[1] TIM-3, a promising target for cancer immunotherapy
He, Yayi
Cao, Jie
Zhao, Chao
Li, Xuefei
Zhou, Caicun
Hirsch, Fred R.
[J]. ONCOTARGETS AND THERAPY, 2018, 11 : 7005 - 7009
[2] The role of TIM-3 in sepsis: a promising target for immunotherapy?
Wang, Changli
Liu, Jinhai
Wu, Qi
Wang, Zhi
Hu, Baoji
Bo, Lulong
[J]. FRONTIERS IN IMMUNOLOGY, 2024, 15
[3] The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
Ganjalikhani Hakemi, Mazdak
Jafarinia, Morteza
Azizi, Mahdieh
Rezaeepoor, Mahsa
Isayev, Orkhan
Bazhin, Alexandr V.
[J]. FRONTIERS IN ONCOLOGY, 2020, 10
[4] TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
Sauer, Natalia
Janicka, Natalia
Szlasa, Wojciech
Skinderowicz, Bartlomiej
Kolodzinska, Katarzyna
Dwernicka, Wioletta
Oslizlo, Malgorzata
Kulbacka, Julita
Novickij, Vitalij
Karlowicz-Bodalska, Katarzyna
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (11) : 3405 - 3425
[5] TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
Natalia Sauer
Natalia Janicka
Wojciech Szlasa
Bartłomiej Skinderowicz
Katarzyna Kołodzińska
Wioletta Dwernicka
Małgorzata Oślizło
Julita Kulbacka
Vitalij Novickij
Katarzyna Karłowicz-Bodalska
[J]. Cancer Immunology, Immunotherapy, 2023, 72 : 3405 - 3425
[6] Targeting TIM-3 as a new strategy in immunotherapy: focus on sabatolimab
Murthy, G. S. Guru
Atallah, E.
[J]. DRUGS OF THE FUTURE, 2021, 46 (11) : 901 - 905
[7] TIM-3: An update on immunotherapy
Zhao, Lizhen
Cheng, Shaoyun
Fan, Lin
Zhang, Bei
Xu, Shengwei
[J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 99
[8] MODIFYING THE TUMOR MICROENVIRONMENT WITH A TIM-3 MONOCLONAL ANTIBODY AS A THERAPEUTIC STRATEGY FOR DIPGS
Ausejo-Mauleon, Iker
Labiano, Sara
De la Nava, Daniel
Garcia-Moure, Marc
Laspidea, Virginia
Becher, Oren J.
Jiang, Li
Filbin, Mariella G.
Pastor, Fernando
Alonso, Marta M.
[J]. NEURO-ONCOLOGY, 2022, 24 : 22 - 23
[9] TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
Du, Wenwen
Yang, Min
Turner, Abbey
Xu, Chunling
Ferris, Robert L.
Huang, Jianan
Kane, Lawrence
Lu, Binfeng
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (03)
[10] Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
Anderson, Ana C.
[J]. CANCER IMMUNOLOGY RESEARCH, 2014, 2 (05) : 393 - 398

← 1 2 3 4 5 →